Lupus Therapeutic Market, by Disease Type (Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, and Neonatal Lupus), by Treatment Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Biologics, Antimalarial
Description
Lupus Therapeutic Market, by Disease Type (Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, and Neonatal Lupus), by Treatment Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Biologics, Antimalarial Drugs, Corticosteroids, and Others {Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others}), by Route of Administration (Oral, Subcutaneous, Intravenous, and Others {Intramuscular, Intradermal, among others}, by End User (Hospitals & Clinics, Diagnostic Laboratories, and Others {Homecare, Specialty Centre, among others}), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Lupus is an autoimmune disorder wherein the immune system of the body attacks body’s own healthy tissues and organs, resulting in swelling, tissue damage, and pain. The inflammation caused by lupus can affect the joints, kidneys, brain, blood cells, skin, heart, and lungs. The exact cause of lupus is unknown, however, certain risk factors are associated with lupus. These risk factors include hormones, genetics, smoking, viral infection, and others. Some of the common symptoms related to lupus include fatigue, muscle and joint pain, fever, mouth ulcers, headaches, arthritis, malar rash, unusual hair loss, and others. Diagnosis of lupus is difficult as its symptoms mimic those of other ailments such as rheumatoid arthritis, scleroderma, etc. However, a butterfly-shaped rash, also known as malar rash across the nose and cheek is a highly distinctive feature of lupus. There are other complications that can arise from lupus, such as urinary tract infections, yeast infections, herpes, pregnancy loss, bone tissue death, and others.
Market Dynamics
The high prevalence and incidence of lupus, rapid research and development activities towards development of novel therapeutics for treatment of lupus, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global lupus therapeutic market over the forecast period.
For instance, according to an article published by the Lupus Science and Medicine journal, in April 2021, it is estimated that the incidence and prevalence of Systemic Lupus Erythematosus (SLE) were around 0.3 to 5.1 per 100 000 per year and 6.5 to 85 per 100 000 population, respectively in Europe in 2020.
Key features of the study:
This report provides an in-depth analysis of the global lupus therapeutic market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global lupus therapeutic market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global lupus therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lupus therapeutic market
Detailed Segmentation:
Global Lupus Therapeutic Market, By Disease Type:
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
Global Lupus Therapeutic Market, By Treatment Type:
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
Global Lupus Therapeutic Market, By Route Of Administration:
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
Global Lupus Therapeutic Market, By End User:
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
Global Lupus Therapeutic Market, By Region:
North America
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
U.S.
Canada
Latin America
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
GCC
Israel
Rest of Middle East
Africa
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Hikma Pharmaceuticals PLC*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Lupus Therapeutics
Dr. Reddy's Laboratories Ltd.
GlaxoSmithKline plc
Amgen Inc.
Novartis AG
Sanofi
UCB S.A.
ImmuPharma PLC
Bayer AG
Merck & Co., Inc.
Aurinia Pharmaceuticals Inc.
Pfizer Inc.
ADMA Biologics, Inc.
AstraZeneca
F.Hoffmann-La Roche Ltd
Bristol-Myers Squibb Company
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Boehringer Ingelheim International Gmbh
“*” marked represents similar segmentation in other categories in the respective section.
Lupus is an autoimmune disorder wherein the immune system of the body attacks body’s own healthy tissues and organs, resulting in swelling, tissue damage, and pain. The inflammation caused by lupus can affect the joints, kidneys, brain, blood cells, skin, heart, and lungs. The exact cause of lupus is unknown, however, certain risk factors are associated with lupus. These risk factors include hormones, genetics, smoking, viral infection, and others. Some of the common symptoms related to lupus include fatigue, muscle and joint pain, fever, mouth ulcers, headaches, arthritis, malar rash, unusual hair loss, and others. Diagnosis of lupus is difficult as its symptoms mimic those of other ailments such as rheumatoid arthritis, scleroderma, etc. However, a butterfly-shaped rash, also known as malar rash across the nose and cheek is a highly distinctive feature of lupus. There are other complications that can arise from lupus, such as urinary tract infections, yeast infections, herpes, pregnancy loss, bone tissue death, and others.
Market Dynamics
The high prevalence and incidence of lupus, rapid research and development activities towards development of novel therapeutics for treatment of lupus, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global lupus therapeutic market over the forecast period.
For instance, according to an article published by the Lupus Science and Medicine journal, in April 2021, it is estimated that the incidence and prevalence of Systemic Lupus Erythematosus (SLE) were around 0.3 to 5.1 per 100 000 per year and 6.5 to 85 per 100 000 population, respectively in Europe in 2020.
Key features of the study:
This report provides an in-depth analysis of the global lupus therapeutic market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global lupus therapeutic market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global lupus therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lupus therapeutic market
Detailed Segmentation:
Global Lupus Therapeutic Market, By Disease Type:
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
Global Lupus Therapeutic Market, By Treatment Type:
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
Global Lupus Therapeutic Market, By Route Of Administration:
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
Global Lupus Therapeutic Market, By End User:
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
Global Lupus Therapeutic Market, By Region:
North America
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
U.S.
Canada
Latin America
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country
GCC
Israel
Rest of Middle East
Africa
By Disease Type
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus
Drug-Induced Lupus Erythematosus
Neonatal Lupus
By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Biologics
Antimalarial Drugs
Corticosteroids
Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
By Route Of Administration
Oral
Subcutaneous
Intravenous
Others (Intramuscular, Intradermal, among others)
By End User
Hospitals & Clinics
Diagnostic Laboratories
Others (Homecare, Specialty Centre, among others)
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Hikma Pharmaceuticals PLC*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Lupus Therapeutics
Dr. Reddy's Laboratories Ltd.
GlaxoSmithKline plc
Amgen Inc.
Novartis AG
Sanofi
UCB S.A.
ImmuPharma PLC
Bayer AG
Merck & Co., Inc.
Aurinia Pharmaceuticals Inc.
Pfizer Inc.
ADMA Biologics, Inc.
AstraZeneca
F.Hoffmann-La Roche Ltd
Bristol-Myers Squibb Company
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Boehringer Ingelheim International Gmbh
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
167 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Disease Type
- Market Snippet, By Treatment Type
- Market Snippet, By Route of Administration
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Treatment Option Analysis
- Alternate/Substitute Landscape
- Treatment Safety and Efficacy Analysis
- Treatment Algorithm (Patient Journey)
- Historical Roadmap of Drug Approvals
- Site of Activity (Mode of Action)
- Drug Resistance Scenario
- Reimbursement Scenario
- Cost of therapy
- Brand Mapping
- Pipeline Analysis
- Epidemiology
- Recent Product Approvals
- Regulatory Scenario
- Health-Technology Assessment
- PEST Analysis
- Mergers, Acquisitions and Collaboration Scenario
- Adherence rate in U.S.
- Switch analysis in U.S.
- Patent Expiry Scenario
- Disease Awareness Programs
- Product Recall
- Risk and Adverse effects
- 4. Global Lupus Therapeutic Market – Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- Impact on Clinical Trials and Drug Development
- Government Initiatives
- 5. Global Lupus Therapeutic Market, By Disease Type, 2017 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Systemic Lupus Erythematosus (SLE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Cutaneous Lupus Erythematosus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Drug-Induced Lupus Erythematosus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Neonatal Lupus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- 6. Global Lupus Therapeutic Market, By Treatment Type, 2017 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Antimalarial Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- 7. Global Lupus Therapeutic Market, By Route of Administration, 2017 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Others (Intramuscular, Intradermal, among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- 8. Global Lupus Therapeutic Market, By End User, 2017 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Hospitals & Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- Others (Homecare, Specialty Centre, among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
- 9. Global Lupus Therapeutic Market, By Region, 2017 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2030
- North America
- Market Size and Forecast, By Disease Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Disease Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Disease Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Disease Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Disease Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Disease Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Treatment Type, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By End User, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- 10. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Hikma Pharmaceuticals PLC
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Lupus Therapeutics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Amgen Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- UCB S.A.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- ImmuPharma PLC
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Aurinia Pharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- ADMA Biologics, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AstraZeneca
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- F.Hoffmann-La Roche Ltd
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Boehringer Ingelheim International Gmbh
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views
- 11. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 49 market data tables and 37 figures on "Global Lupus Therapeutic Market” - forecast to 2030
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
